[1]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77-80.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
　WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):77-80.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
点击复制

TRAb水平测定在Graves眼病中的临床意义探讨(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第2期
页码:
77-80
栏目:
论著
出版日期:
2013-03-25

文章信息/Info

Title:
The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy
作者:
王朝点;  史育红;  颜兵
成都市核工业四一六医院核医学科, 成都, 610051
Author(s):
WANG Chao-dian;  SHI Yu-hong;  YAN Bing
Department of Nuclear Medicine, Nuclear Industry 416 Hospital of Chengdu, Chengdu 610051, China
关键词:
格雷夫斯病; Graves眼病; 促甲状腺激素受体抗体
Keywords:
Graves disease; Graves ophthalmopathy; Thyrotrophin receptor antibody
DOI:
10.3760/cma.j.issn.1673-4114.2013.02.004
摘要:
目的 探讨血清促甲状腺激素受体抗体(TRAb)在Graves眼病发病机制中的作用。方法 选择初发Graves病患者219例,其中,Graves眼病组121例,无Graves眼病组98例,血清检测甲状腺功能、甲状腺过氧化物酶抗体(TPOAb)、甲状腺球蛋白抗体(TgAb)和TRAb水平,并根据欧洲Graves眼病专家组共识进行Graves眼病临床活动性评分(CAS)和严重程度评估。结果 Graves眼病组和非Graves眼病组的血清游离三碘甲状腺原氨酸、游离甲状腺素、TPOAb、TgAb和TRAb水平差异均无统计学意义,TRAb水平与Graves眼病病情的严重程度和CAS之间无相关关系。结论 Graves眼病患者的CAS和病情的严重程度与TRAb水平之间不存在相关关系,因此,TRAb水平与Graves眼病的关系还需要进一步研究。
Abstract:
Objective To explore the value of serum thyrotrophin receptor antibody (TRAb) on the pathological mechanism of Graves ophthalmopathy.Methods Two hundred and nineteen newly diagnosed Graves disease patients who were divided into Graves ophthalmopathy group (n=121) and without Graves ophthalmolpathy group (n=98) were tested serum concentration with thyroid function,thyroperoxidase antibodies (TPOAb),thyroglobulin antibodies (TgAb) and TRAb.According to the consensus statement of the European Group on Graves ophthalmopathy,clinical activity score (CAS)and severity evaluation were carried out on Graves ophthalmopathy patients.Results There was no significant difference in serum concentration of free thyroxine (FT4),free triiodothyronine (FT3),TPOAb and TRAb between the Graves ophthalmopathy group and the without Graves ophthalmopathy group.Serum concentration of TRAb was not correlated with the severity and CAS of Graves ophthalmopathy.Conclusions The CAS and the severity of Graves ophthalmopathy were irrelevant to the serum concentration of TRAb.Therefore,the correlation between TRAb and Graves ophthalmopathy still needs further study.

参考文献/References:

[1] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南——甲状腺功能亢进症.中华内科杂志,2007,46(10):876-882.
[2] Bartley GB,Gorman CA.Diagnostic criteria for Graves’ ophthal-mopathy.A m J Ophthahnol,1995,119(6):792-795.
[3] 孟召伟,谭建.解读美国甲状腺学会和临床内分泌医师协会2011年甲亢诊治指南.国际放射医学核医学杂志,2011,35(4):193-201.
[4] 吕红彬,黄新文,罗清礼,等.CT在甲状腺相关眼病中的诊断价值.四川大学学报:医学版,2007,38(1):167-169.
[5] Marcocci C,Bartalena L,Bogazzi F,et al.Studies on the occurrenceof ophthalmopathy in Graves’ disease.Acta Endocrinol,1989,120(4):473-478.
[6] Brent GA.Graves’ disease.N Engl J Med,2008,358(24):2594-2605.
[7] Subekti I,Boedisantoso A,Moeloek ND,et al.Association of TSH receptor antibody,thyroid stimulating antibody,and thyroid block-ing antibody with clinical activity score and degree of severity of Graves ophthalmopathy.Acta Med Indones,2012,44(2):114-121.
[8] 陆再英,钟南山.内科学.7版.北京:人民卫生出版社,2008:717.
[9] Crisp MS,Lane C,Halliwell M,et al.Thyrotropin receptor tran-scripts in human adipose tissue.J Clin Endocrinol Metab,1997,82(6):2003-2005.
[10] Feliciello A,Porcellini A,Ciullo I,et al.Expression of thyrotropin-receptor mRNA in healthy and Graves’ disease retro-orbital tissue.Lancet,1993,342(8867):337-338.
[11] Boschi A,Daumerie Ch,Spiritus M,et al.Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thy-roid associated orbitopathy.Br J Ophthalmol,2005,89(6):724-729.
[12] 宋补昌,李宝兰,孙斌.血清TRAb检测对Graves病突眼的应用价值.放射免疫学杂志,2005,18(6):478-479.
[13] 唐武儒,韦南仕.TRAb水平测定在甲亢并突眼治疗中的意义探讨.右江民族医学院学报,2006,28(1):56.
[14] 王亚萍,肖锦华,朱华燕,等.全自动电化学发光免疫分析法检测血清TRAb的方法学评价.放射免疫学杂志,2011,24(6):661-664.
[15] 何建华,曾钦文,TSH受体抗体及临床意义.国外医学:放射医学核医学分册,2001,25(3):111-114.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[4]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[5]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[6]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[7]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[8]苏丹,赵水喜.甲状腺相关眼病的放射治疗进展[J].国际放射医学核医学杂志,2014,38(2):126.[doi:10.3760/cma.j.issn.1673-4114.2014.02.012]
　Su Dan,Zhao Shuixi.The development of radiotherapy for thyroid associated ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):126.[doi:10.3760/cma.j.issn.1673-4114.2014.02.012]
[9]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
　Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[10]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[11]段炼,陆克义,陈霞,等.131I治疗Graves病对甲状腺相关眼病转归的相关因素分析[J].国际放射医学核医学杂志,2011,35(4):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
　DUAN Lian,LU Ke-yi,CHEN Xia,et al.Related factors of thyroid-associated ophthalmopathy in patents with Graves’ disease after 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(2):230.[doi:10.3760/cma.j.issn.1673-4114.2011.04.009]
[12]赵炎,王俊起,沈婕.Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析[J].国际放射医学核医学杂志,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
　Zhao Yan,Wang Junqi,Shen Jie.131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]

备注/Memo

备注/Memo:
收稿日期:2012-11-14。
基金项目:四川省卫生厅项目(项目编号:2010100183)
通讯作者:史育红,Email:shiyuhong89@hotmail.com
更新日期/Last Update: 1900-01-01